Comparative Pharmacology
Head-to-head clinical analysis: KENACORT versus TRIESENCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENACORT versus TRIESENCE.
KENACORT vs TRIESENCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell migration.
Corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Kenacort (triamcinolone acetonide) is a corticosteroid. For adults, typical dosing is 40-80 mg intramuscularly (deep intragluteal) as a single injection; oral tablets: 4-48 mg/day divided every 6-12 hours; intra-articular: 5-40 mg depending on joint size.
1 to 4 mg (0.025 to 0.1 mL of 40 mg/mL suspension) intravitreal injection once.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (triamcinolone acetonide). Clinical context: Short half-life supports alternate-day dosing for chronic conditions; however, adrenal suppression may persist longer.
Approximately 3.3 hours for triamcinolone acetonide; with intravitreal administration, detectable levels persist for weeks to months.
Renal: 25-30% as unchanged drug and metabolites. Biliary/fecal: 50-70% as metabolites, with enterohepatic circulation.
Primarily hepatic metabolism; renal excretion of metabolites (<5% unchanged). Biliary/fecal elimination accounts for minimal clearance.
Category C
Category C
Corticosteroid
Corticosteroid